Drug Profile


Alternative Names: ZP 1848

Latest Information Update: 26 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Short bowel syndrome
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 19 Jun 2017 Interim efficacy data, adverse events data and pharmacokinetics data from a phase II trial in Short bowel syndrome released by Zealand Pharma
  • 17 May 2017 Zealand Pharma completes a phase II trial in Short bowel syndrome in Denmark
  • 06 Feb 2017 Zealand Pharma completes enrolment in its phase II trial for Short bowel syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top